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Abstract Cell-to-substratum adhesion becomes weakened uring mitosis of the cell cycle in fibroblasts. The level of one focal adhesion protein, 
paxillin, is greatly reduced in mitotic-arrested cells. We show here the possible involvement of calpain II, known to be localized in fecal adhesion 
plaques, in the degradation ofpaxillin. Paxillin is tyrosine-phosphorylated during interphase ofthe cell cycle by protein tyrosine kinases (PTK) such 
as c-Src and Csk, and becomes dephosphorylated during mitosis. Our data, however, indicate that tyrosine phosphorylation f paxillin does not a&ct 
the rate of paxillin degradation by calpain in vitro. 
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1. Introduction 
Adherent cells contact the extracellular matrix (ECM) 
through distinct clusters of integrins. Complex structures of 
proteins, called focal adhesion plaques, appear when ceils are 
spread on ECM-coated culture dishes. Proteins in this complex 
include paxillin, focal adhesion kinase, talin, tensin, and vin- 
culin. During mitosis, most focal adhesion plaques are disas- 
sembled. When we examined the expression of focal adhesion 
proteins in NIH3T3 cells arrested in the M-phase by noco- 
dazole, we saw a reduction in the level of paxillin [l]. In con- 
trast, other focal adhesion proteins did not show altered expres- 
sion ([l]; R.Y. and H.S., unpublished). 
In well-spread fibroblasts, paxillin is multiply phosphor- 
ylated during interphase (Sabe et al., submitted). Phosphoryla- 
tion of paxillin occurs soon after cells are plated on tissue 
culture dishes [2]. Both c-Src and Csk protein tyrosine kinases 
are known to phosphorylate paxillin in vitro, although as differ- 
ent isoforms ([l]; Sabe et al., submitted). In mitotic cells, as well 
as cells that are trypsinized and suspended in medium, only the 
dephosphorylated form of paxillin is recovered [1,2]. 
Beckele et al. have found that calpain II localizes at focal 
adhesion plaques [3]. Furthermore, they found that among 
several focal adhesion proteins tested, talin was a good in vitro 
substrate for calpain II. Vinculin and a-actinin could not be 
digested by calpain II in vitro [3]. The existence of paxillin was 
unknown at the time. 
In this report, the possible involvement of calpain II and a 
closely related protease, calpain I, in the degradation of paxillin 
was examined. We report that paxillin is a good substrate for 
calpains in vitro. We also found that paxillin phosphorylated 
in vitro by either c-Src or Csk kinase is just as efficiently de- 
graded by calpain II. 
2. Materials and methods 
2.1. Materials 
Calpain I and calpain II were purified from human erythrocytes and 
human placenta, respectively, asdescribed [4]. Recombinant human 
calpastatin domain 1 was prepared as described [5]. Recombinant Csk 
and recombinant oSrc were described previously [1,6]. An anti-paxillin 
antibody was purchased from Zymed (San Francisco, CA). 
2.2 Cell culture 
NIH3T3 cells were cultured as described [l]. Mitotic cells were pre- 
pared by incubating cells with 0.4 @ml of nocodazole (Sigma) for 7.5 
h at 37°C [7l and harvested by shaking off from culture dishes. To keep 
the cells in suspension, the cells were trypsinized, washed twice with 
Dulbecco’s modified Eagle’s medium containing soybean trypsin inhib- 
itor (0.5 mg/ml), suspended in culture medium, and loaded onto culture 
dishes precoated with agar (1.8% agar in culture medium). 
2.3. Immunoblotting analysis 
Cell lysates were prepared in RIPA buffer [S], and each 5Opg of lysate 
protein was separated by SDS-PAGE (8%), transferred to Immobilon- 
P filter membranes (Millipore), and subjected to immunoblotting anal- 
ysis using an anti-paxillin antibody (Zymed) as described [Il. Antibody 
retained on filters was visualized by ECL (Amersham). To visualize 
cellular proteins transferred onto filters, filters were stained with 
Coomassie brilliant blue R-250 (0.1% in 50% methanol) for 10 min at 
ambient temperature, followed by destaining with a methanol/acetic 
acid/water (5: 1:4) solution. 
2.4. Paxillin and its digestion by calpain in vitro 
Paxillin was immunoprecipitated from cell lysates prepared with 
RIPA buffer using an anti-paxillin antibody coupled with protein G- 
Sepharose beads. After washing, paxillin was eluted from beads with 
0.1 M glycine-HCl @H 2.5) and neutralized with 70 mM Tris-HCl @H 
8.8) containing 0.2%j?-mercaptoethanol and 1 mg/ml acetylated bovine 
serum albumin as described [9,10], then dialyzed against a buffer con- 
taining 20 mM Tris-HCl (pH 7.4), 0.14 M NaCI and 1 mM EDTA. In 
vitro phosphorylation of paxillin was carried out in a kinase buffer (50 
mM Tris-HCl (pH 7.4), 0.1 mM Na,VO,, 0.1% Nonidet P-40, 3 mM 
MgCl,, 3 mM MnCl,, 1 mg/ml acetylated bovine serum albumin, 10pM 
ATP) in the presence of each 0.1 pg of recombinant Csk or recombinant 
c-Src, and incubated for 30 min at 37’C. 
*Corresponding author. Fax: (81) (75) 761 5766. 
In vitro digestion of paxillin by calpain was carried out in a buffer 
(20 mM Tris-HCl @H 7.5), 5 mM CaCl,, 5 mM /I-mercaptoethanol, 50 
mM NaCl) containing paxillin and calpain for 30 min at 30 “C. Samples 
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were separated by SDS-PAGE (8%) and analyzed by immunoblotting 
using an anti-paxillin antibody. 
3. Results 
To con&m that the decrease in the level of paxillin in mitotic- 
arrested cells [l] is not due to thegeneral degradation of cellular 
proteins, cellular proteins from the mitotic-arrested cells were 
separated by SDS-PAGE and stained with Coomassie brilliant 
blue R-250. As shown in Fig. 1, little change in the amount of 
each cellular protein was observed in the mitotic-arrested cells 
compared with that in cells growing on culture dishes, although 
probing of the same filter with an anti-paxillin antibody re- 
vealed a marked decrease in levels of paxillin in mitotic-arrested 
cells (Fig. 1). 
Cell adhesion to the ECM in fibroblasts is greatly reduced 
during mitosis. We therefore examined whether the decrease in 
the level of paxillin is due merely to the loss of cell adhesion. 
Cells grown on tissue culture dishes were harvested by trypsini- 
zation and kept in suspension. As shown in Fig. 2, no change 
in the level of paxillin was seen for up to 10 h in cells kept in 
suspension. Therefore, the loss of cell to substratum adhesion 
per se did not affect the level of paxillin. 
Since calpain II localizes at focal adhesion plaques, the pos- 
sible degradation of paxillin by calpain II was examined. As 
shown in Fig. 3, paxillin was a good substrate for calpain II in 
vitro. Calpain I, is closely related to calpain II in its substrate 
specificity in vitro, but requires a much lower concentration of 
calcium (I-1OpM) for its activation. Calpain I does not localize 
to the adhesion plaques [3]. We found that Calpain I also 
degraded paxillin (Fig. 3). Degradation of paxillin by both 
calpains was totally inhibited by the inhibitor calpastatin (Fig. 
3). 
Paxillin is dephosphorylated uring mitosis [l]. We postu- 
lated that tyrosine phosphorylation may be a signal that pro- 
tects paxillin from degradation by protease during interphase 
of the cell cycle. We examined whether tyrosine phosphoryla- 
tion of paxillin could affect its degradation by calpains. Previ- 
ously we have shown that paxillin is tyrosine-phosphorylated 
at multiple sites in normal fibroblasts, and Csk and oSrc are 
involved in this multiple tyrosine phosphorylation (fl]; Sabe et 
al., submitted). Thus, paxillin was phosphorylated in vitro by 
kDa L ’ L ’ 
200- 
97.4- 
69- 
46- 
30- 
Coomassie a pax blot 
Fig. 1. Disappearance of paxillin in mitotic-arrested fibroblasts. 
NIH3T3 cells growing on culture dishes (L) or arrested at mitosis bv , 
nocodazole treatment(M) were lysed and &llular proteins were sepa- 
rated by SDS-PAGE (8%) and transferred onto a filter for immunoblot 
analysis. The Iilter was then probed with an anti-paxillin antibody 
@Pax). Proteins on the filter were also visualized by staining the filter 
with Coomassie brilliant blue R250 (Coomassie). 
in suspension (hr) 
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Fig. 2. Levels of paxillin were unaffected by the loss of cell to substra- 
tum adhesion. Cell lvsates were DreDared from NIH 3T3 cells keot in 
suspension for up to 10 h as indicated, and levels of paxillin were 
analyzed as in Fig. 1 after proteins were separated by SDS-PAGE. As 
a control, NIH 3T3 cells were grown on a tissue culture dish (on dish) 
for the same period. 
Csk or by c-Src, and subjected to incubation with calpain II. 
As seen in Fig. 3, tyrosine phosphorylated paxillin migrated 
more slowly on SDS-PAGE than the unphosphorylated form. 
Tyrosine phosphorylation of these slow-migrating forms of 
paxillin was confirmed by immunoblotting using an anti- 
phosphotyrosine antibody (data not shown). As shown in Fig. 
3, tyrosine-phosphorylation of paxillin either by Csk or by c-Src 
did not protect it from digestion by calpain II in vitro. 
4. Discussion 
We believe that the degradation of paxillin seen in noco- 
dazole-treated NIH3T3 cells is a mitosis-specific event. In other 
studies, we have treated rat 3Yl fibroblasts, CHO cells as well 
as mouse NIH3T3 cells with nocodazole or other pharmacol- 
ogical agents, and found that paxillin is specifically degraded 
in mitotic cells, but not in the similarly treated interphase cells 
(R.Y. and H.S., unpublished). In cells treated with a low dose 
of nocodazole, so that they can recover and exit mitosis, pax- 
illin is nevertheless degraded during mitotic arrest, yet reap- 
pears as cells enter the interphase (R.Y. and H.S., unpublished). 
Calpain II has been proposed to be involved in the meta- 
phase/anaphase transition. Micro-injection of labeled calpain 
II into synchronized PtK cells revealed that calpain II translo- 
cates from the plasma membrane to the nucleus during mitosis 
[ 111. Indeed, micro-injection of calcium during metaphase stim- 
ulates the transition to anaphase [121, and conditions that lower 
the cytoplasmic calcium concentration delay the onset of ana- 
phase [13]. 
Our in vitro study suggested that calpain II might be respon- 
sible for the mitotic-specific degradation of paxillin. Talin can 
also be digested by calpain II in vitro [3]. We have detected a 
proteolytic fragment of talin, as has been reported [ 141, in both 
cells at interphase and in cells arrested at mitosis (R.Y. and 
H.S., unpublished). However, levels of intact talin and the 
proteolytic fragment did not change during mitosis when com- 
pared to the levels in interphase cells (R.Y. and H.S., unpub- 
lished). Further analysis will be required to confirm the involve- 
ment of calpain in the decreased level of paxillin during mitosis 
as well as in proteolysis of talin. 
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Fig. 3. Degradation ofunphosphorylated and phosphorylated paxillin 
by calpains. (a) Paxillin immuno-purified from NIH3T3 cells was sub- 
jected to ealpaiu treatment in vitro either with 30 mU of ealpain I or 
calpain II, in the absence or presence of0.2 ,ug of recombinant calpas- 
tatin. Samples were then separated by SDS-PAGE and subjected to 
immunoblotting analysis using an anti-paxillin antibody. (bd) Paxillin 
immuno-purified (b) or tyrosine-phosphorylated in vitro by c-Src (c) or 
by Csk (d) were treated with various concentrations of calpain II: lane 
1, none; lane 2, 6 mu; lane 3, 15 mu; lane 4, 37 mu; lane 5, 37 mU 
plus 0.2 pg of calpastatin. Samples were separated by SDS-PAGE and 
analyzed by immtmoblotting with anti-paxillin antibody as in Fig. 1. 
It is not known whether levels of cellular calcium at focal 
coqtacts prior to or during mitosis are high enough to activate 
calpain II. A rapid elevation of the free calcium concentration 
(up to 500-800 nM) at the metaphaselanaphase transition [15], 
and an elevation of the calcium concentration at the mitotic 
spindle poles during anaphase [161 has been reported. However, 
this level of calcium is still far below that which is required to 
activate calpain II in vitro (200-300 PM of calcium). Other 
mechanisms uch as a decrease in the calcium requirement of 
calpain by its autoproteolysis [17-191 or the presence of 
phospholipids including phosphatidyIinositol[2C-221 may par- 
ticipate in its activation in vivo. In this regard, it is noteworthy 
that cell to substratum adhesion triggers an increase in the 
cellular free calcium concentration up to several PM [23,24]. 
Phospholipid turnover can also be enhanced by cell to substra- 
tum adhesion [25]. 
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Lastly, our in vitro study showed that calpain II degraded 
paxillin regardless of whether paxillin is phosphorylated by 
c&c or Csk or not phosphorylated. Of course, this may not 
reflect what happens in viva. Notably tyrosine phosphorylation 
of paxilhn is known to induce its association with SH2 domains 
of Csk [l] and v-Crk [26]. Thus it is still possible that formation 
of complexes with other proteins as a result of tyrosine phos- 
phorylation of paxilhn may induce sequestering of cleavage 
sites of paxillin from calpain. 
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